Cenduit LLC, a provider of services to the pharmaceutical, biopharmaceutical and medical device industries, has been chosen as a finalist for the North Carolina Technology Association’s (NCTA) 21 Awards.

The NCTA 21 Awards recognize excellence, innovation and leadership in technology in 21 categories. The NCTA’s mission is to make North Carolina the No. 1 state in technology leadership by supporting technology initiatives and education throughout the state.

Cenduit competed against hundreds of North Carolina-based technology companies to reach the finals.

According to Dr. Jogin Desai, Cenduit Chief Executive Officer, Cenduit focuses on its superior interactive response technology (IRT) in order to deliver services to clinical trials around the world and strives to provide the best possible IRT experience for its clients.

“Cenduit continues to invest in the latest technology and systems that enable sponsors and investigator sites to easily randomize patients and manage their drug supplies,” Desai said. “We’re proud to be selected as a finalist by the NCTA and recognized as a leader in our space.”

Cenduit’s IRT solutions deliver precise control over patient randomization and the logistics of drug supply management to enable more efficient, regulatory-compliant trials. Cenduit’s IRT solutions are currently deployed at more than 16,000 sites in more than 100 countries.

The winners will be announced November 8.

About Cenduit LLC
Cenduit provides interactive response technology (IRT) - driven services for clinical trials around the world. Cenduit’s IRT solutions deliver optimized clinical supply chain management and facilitate precise control over patient randomization and drug administration to enable more efficient, compliant trials. With expert personnel located across the globe, Cenduit’s unprecedented level of support currently covers more than 16,000 sites in more than 100 countries. Focus on trials, not tribulations, with Cenduit. For more information or to connect with Cenduit, visit www.cenduit.com.